1. Catalogs
  2. Randox Laboratories
  3. MRSA/SA – Emerging Therapeutic & Screening Approaches

MRSA/SA – Emerging Therapeutic & Screening Approaches

MRSA/SA – Emerging Therapeutic  & Screening Approaches

MRSA/SA – Emerging Therapeutic & Screening Approaches

Product catalog summary
Introduction
Staphylococcus aureus is a gram-positive bacterium part of human flora, capable of causing severe diseases if it invades internal tissues or the bloodstream. Antimicrobial resistance (AMR) poses a global health threat, with Methicillin-Resistant Staphylococcus aureus (MRSA) being particularly concerning due to its resistance to β-lactam antibiotics.

Methicillin-Resistant Staphylococcus aureus (MRSA)
MRSA exhibits resistance to multiple antibiotics, including β-lactams, macrolides, tetracyclines, and fluoroquinolones. It spreads through direct contact or fomites and is classified into community-acquired (CA-MRSA) and hospital-acquired (HA-MRSA) infections. The high prevalence of MRSA necessitates rapid testing and prompt treatment.

Resistance Mechanisms
MRSA resistance stems from genetic mutations and horizontal gene transfer. The mecA gene encodes PBP-2a, reducing β-lactam affinity. Biofilm formation further enhances resistance to antimicrobial agents.

Current and Emerging Therapeutic Strategies
While vancomycin and daptomycin are current treatments for MRSA, resistance is developing. New therapies like antimicrobial peptides (AMPs) and silver nanoparticles (AgNPs) show promise. AMPs disrupt bacterial membranes, and AgNPs damage cellular components and induce reactive oxygen species.

Screening, Testing & Evaluation
Traditional MRSA detection methods are slow. Rapid PCR techniques, such as the Bosch Vivalytic MRSA/SA test, deliver results in under an hour, facilitating timely treatment. This automated system minimizes the need for extensive lab equipment.

Conclusion
Effective MRSA treatment and infection control rely on rapid, accurate detection. Emerging therapies and advanced screening methods offer promising solutions to combat MRSA and mitigate the impact of AMR.
See more

Catalog excerpts

MRSA/SA – Emerging Therapeutic  & Screening Approaches-1

EDUCATIONAL GUIDE MRSA/SA – Emerging Therapeutic & Screening Approaches

 Open the catalog to page 1
MRSA/SA – Emerging Therapeutic  & Screening Approaches-2

Introduction Staphylococcus aureus is a gram positive, commensal bacteria found in normal human flora on the skin and mucous membranes. The commensal nature of this organism results in colonisation of around half of the general population, rising to around 80% in populations of healthcare workers, hospitalised patients and the immunocompromised1. However, given the opportunity to colonise internal tissues or the bloodstream, S. aureus infection can cause serious disease. Skin conditions caused by S. aureus include impetigo, scalded skin syndrome, boils, and abscesses. Examples of more serious...

 Open the catalog to page 2
MRSA/SA – Emerging Therapeutic  & Screening Approaches-3

Identification of drug-resistant strains of bacteria is crucial to allow for characterisation of the pathogen and correct treatment of the infection. Classical evaluation consists of a routine culture to verify a diagnosis based on presenting symptoms. However, this can be a time consuming and laborious process which may delay diagnosis and treatment of a potentially fatal infection1. Methicillin-Resistant Staphylococcus aureus Methicillin is of a class of antibiotics known as β-lactams which bind to the penicillin binding protein (PBP) of the bacteria. PBP is responsible for crosslinking between...

 Open the catalog to page 3
MRSA/SA – Emerging Therapeutic  & Screening Approaches-4

The first mechanism of resistance is the expression of β-lactamase which functions to degrade β-lactams, ultimately resulting in loss of function of the antibiotic. This enzyme hydrolyses β-lactam ions in the periplasmic space, denaturing the antibiotic before it can interact with bacteria3. The mecA gene encodes the protein penicillin-binding protein 2a (PBP-2a), a type of PBP which has lower affinity for β-lactams, as well as other penicillin-like antibiotics, due its conformation, meaning that the presence of these antimicrobial agents does not confer a loss of structure in the bacterial cell...

 Open the catalog to page 4
MRSA/SA – Emerging Therapeutic  & Screening Approaches-5

Non-membrane disruptive AMPs require much more investigation; however, it is accepted that these AMPs enter the cell, reacting with important intracellular components inhibiting protein and nucleic acid synthesis, cell division and protease activity3. Silver nanoparticles (AgNPs) exhibit broad spectrum antimicrobial properties through various mechanisms of action. These nanosized particles boast increased antimicrobial properties due to an increased surface area per volume ratio. The first mechanism of action to note is AgNPs direct adhesion to the bacterial membrane, which alters the structural...

 Open the catalog to page 5
MRSA/SA – Emerging Therapeutic  & Screening Approaches-6

Vivalytic MRSA/SA Bosch Vivalytic MRSA/SA is an automated, qualitative, in vitro diagnostic test based on real-time PCR for the detection and differentiation of Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive Staphylococcus aureus (MSSA) DNA from human nasal- or oropharyngeal swabs to aid in the diagnosis of MRSA infection of symptomatic or asymptomatic individuals, providing results in less than 1 hour. Rapid PCR MRSA/SA Screening - Bacterial Differentiation to Promote Targeted Therapy Patient presents with symptoms Specimen collected and sent for testing 4 - 36...

 Open the catalog to page 6
MRSA/SA – Emerging Therapeutic  & Screening Approaches-7

Murray CJ, Ikuta KS, Sharara F, et al. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. The Lancet. 2022;399(10325):629-655. doi:https://doi.org/10.1016/S0140-6736(21)02724-0 2. Nandhini P, Kumar P, Mickymaray S, Alothaim AS, Somasundaram J, Rajan M. Recent Developments in Methicillin-Resistant Staphylococcus aureus (MRSA) Treatment: A Review. Antibiotics. 2022;11(5):606. doi:https://doi.org/10.3390/antibiotics11050606 3. Masimen MAA, Harun NA, Maulidiani M, Ismail WIW. Overcoming Methicillin-Resistance Staphylococcus aureus (MRSA) Using Antimicrobial Peptides-Silver...

 Open the catalog to page 7
MRSA/SA – Emerging Therapeutic  & Screening Approaches-8

Copyright © 2023 Randox Laboratories Ltd. All rights Reserved. VAT number: GB 151682708. Product availability may vary from country to country. Some products may be for Research Use Only. For more information on product application and availability, please contact your local Randox Representative.

 Open the catalog to page 8

All Randox Laboratories catalogs and technical brochures

  1. Acusera 24.7

    24  Pages

  2. sdLDL-C

    8  Pages

  3. RX modena

    20  Pages

  4. RX misano

    20  Pages

  5. RX Daytona Plus

    20  Pages

  6. Rx Imola

    20  Pages

  7. RX Monaco

    20  Pages

  8. VeraSTAT-V

    16  Pages

  9. VERASTAT

    16  Pages

  10. Qnostics

    52  Pages

  11. Linearity sets

    12  Pages

  12. Antioxidants

    16  Pages

  13. VIVALYTIC

    30  Pages

  14. HbA1c

    2  Pages

  15. Preparing QC

    1  Page

*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.